secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2026-08-28T21:00:55+00:00
Accession:  0001140361-26-034857
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics shareholders approve Vertex merger; closing expected Sept 1, 2026
---------------------------------------------------------------------------

- Merger adoption approved: 79,240,098 for, 13,618 against, 10,915 abstain.
- Quorum of 74.71% (79,264,631 of 106,095,205 shares) represented at special meeting.
- Non-binding advisory compensation proposal rejected: 33,854,149 for, 44,803,403 against.
- Advisory vote failure not a condition; final closing condition now satisfied.
- Closing of Vertex acquisition expected on or about September 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126034857/0001140361-26-034857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000114036126034857/ef20080970_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-034857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer